<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04694586</url>
  </required_header>
  <id_info>
    <org_study_id>2019-003721-25</org_study_id>
    <nct_id>NCT04694586</nct_id>
  </id_info>
  <brief_title>Drug Exposure and Safety of a Shorter Tuberculosis Treatment Based on High-Dose Rifampicin and Pyrazinamide</brief_title>
  <acronym>HIGHSHORT-RP</acronym>
  <official_title>A Prospective Multicenter Phase II-study: Pharmacokinetics and Safety of High-Dose Rifampicin and Pyrazinamide in a Shorter Tuberculosis Treatment Compared With Standardized Treatment in Patients With Mild to Moderate Pulmonary TB</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Linkoeping</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Linkoeping University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Linkoeping</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tuberculosis (TB) treatment is long and complex with the risk of poor treatment adherence and&#xD;
      treatment failure. Several attempts to shorten treatment of drug-susceptible TB have been&#xD;
      unsuccessful. However, recent data support a shortened regimen for mild and moderate&#xD;
      pulmonary TB and simultaneous optimization of rifampicin (RIF) and pyrazinamide (PZA).&#xD;
&#xD;
      This phase II clinical study aim to investigate a strategy to shorten TB treatment by&#xD;
      exploring safety and drug exposure of a high-dose sterilizing TB regimen.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In five sites in Sweden (Linköping, Norrköping, Jönköping, Kalmar and Stockholm), 40&#xD;
      consenting adult patients with mild to moderate drug-susceptible pulmonary TB will be&#xD;
      recruited. The term Actual Study Start Date (stated 23rd of November 2020) refers to when the&#xD;
      study opened for recruitment and this date will be updated once the first patient is enrolled&#xD;
      in the trial.&#xD;
&#xD;
      The study participants are randomized to receive either 6-month standardized TB treatment&#xD;
      (n=10) or a 4-month regimen (n=30) of rifampicin (RIF) 35 mg/kg and isoniazid (INH) 5 mg/kg&#xD;
      complemented the first 8 weeks by pyrazinamide (PZA) 40 mg/kg and ethambutol (EMB) 15-20&#xD;
      mg/kg.&#xD;
&#xD;
      First-line drug concentration is determined at 0, 1, 2, 4, 6, 8, 12 and 24 h Day 1 and Week 2&#xD;
      and potential side effects thoroughly monitored throughout the study.&#xD;
&#xD;
      Early bactericidal activity (EBA) and sputum culture conversion are evaluated by time to&#xD;
      culture positivity (TTP) in liquid medium system BACTEC MGIT (MGIT, mycobacteria growth&#xD;
      indicator tube) 960 of induced sputum samples collected at day 0, 5 and at week 1, 2 and 8&#xD;
      after treatment initiation.&#xD;
&#xD;
      Clinical symptoms are assessed by a clinical scoring tool (TBscore II). Final treatment&#xD;
      outcome and occurrence of relapse after the end of treatment are recorded according to World&#xD;
      Health Organization (WHO) definitions.&#xD;
&#xD;
      Peak drug concentration (Cmax) and area under the plasma concentration-time curve (AUC) 0-24h&#xD;
      will be estimated by non-compartmental analysis and conditions for early therapeutic drug&#xD;
      monitoring (TDM) of high-dose RIF/PZA will be explored by model-based analysis.&#xD;
&#xD;
      Primary and main secondary outcomes in the study are the distribution of pharmacokinetics&#xD;
      (Cmax, AUC) of high-dose PZA/RIF regimen, safety in terms of incidence of adverse&#xD;
      event/severe adverse event (AE/SAE) probably related or related to TB treatment, and drug&#xD;
      exposure (AUC) of high-dose PZA/RIF in relation to Mycobacterium tuberculosis (Mtb)&#xD;
      drug-susceptibility level (MIC) compared with standard-of-care and suggested&#xD;
      literature-derived pharmacokinetic/pharmacodynamic (PK/PD) targets.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 23, 2020</start_date>
  <completion_date type="Anticipated">May 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC) of 40 mg/kg PZA in a high-dose RIF regimen compared with standard-of-care</measure>
    <time_frame>At treatment Day 14</time_frame>
    <description>PZA AUC(0-24h) at Day 14 after treatment initiation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of 35 mg/kg RIF and 40 mg/kg PZA compared with standard-of-care: AE and SAE</measure>
    <time_frame>4 months in the intervention arm, 6 months in the control arm</time_frame>
    <description>Registration of AE/SAE (incidence, severity, drug relatedness, leading to early withdrawal, and leading to death)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of 40 mg/kg PZA in a high-dose RIF regimen compared with standard-of-care</measure>
    <time_frame>At treatment Day 14</time_frame>
    <description>PZA Cmax at Day 14 after treatment initiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC) of high-dose RIF in combination with PZA 40 mg/kg compared with standard-of-care</measure>
    <time_frame>At treatment Day 14</time_frame>
    <description>RIF AUC(0-24h) at Day 14 after treatment initiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of high-dose RIF in combination with PZA 40 mg/kg compared with standard-of-care</measure>
    <time_frame>At treatment Day 14</time_frame>
    <description>RIF Cmax at Day 14 after treatment initiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug exposure of PZA 40 mg/kg in relation to Mtb drug-susceptibility level (MIC) compared with standard-of-care and literature-derived suggested PK/PD targets</measure>
    <time_frame>Day 0 (MIC) and Day 14 (AUC)</time_frame>
    <description>PZA AUC/MIC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug exposure of RIF 35 mg/kg in relation to Mtb drug-susceptibility level (MIC) compared with standard-of-care and literature-derived suggested PK/PD targets</measure>
    <time_frame>Day 0 (MIC) and Day 14 (AUC)</time_frame>
    <description>RIF AUC/MIC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prediction of PZA pharmacokinetics at steady state (Day 14) based on drug concentration measurement at treatment Day 1</measure>
    <time_frame>At treatment Day 1 (first dose) and Day 14</time_frame>
    <description>PZA AUC(0-24h) at Day 1 compared with PZA AUC(0-24h) at Day 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prediction of RIF pharmacokinetics at steady state (Day 14) based on drug concentration measurement at treatment Day 1</measure>
    <time_frame>At treatment Day 1 (first dose) and Day 14</time_frame>
    <description>RIF AUC(0-24h) at Day 1 compared with RIF AUC(0-24h) at Day 14</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Tuberculosis, Pulmonary</condition>
  <arm_group>
    <arm_group_label>High-dose rifampicin and pyrazinamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rifampicin 35 mg/kg for 4 months provided as a combination of fixed drug combination tablets (HRZE for 8 weeks and HR Week 9-16) and single drug tablets of rifampicin (R)&#xD;
AND&#xD;
pyrazinamide 40 mg/kg the first 2 months provided as a combination of fixed drug combination tablets (HRZE) and single drug tablets of pyrazinamide (Z)&#xD;
fixed drug combination tablets are: isoniazid 75 mg + rifampicin 150 mg + pyrazinamide 400 mg + ethambutol 275 mg (HRZE) combination tablets for 8 weeks AND isoniazid 75 mg + rifampicin 150 mg (HR) combination tablets for Weeks 9 to 16 (total treatment duration 4 months)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standardized TB treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>isoniazid 75 mg + rifampicin 150 mg + pyrazinamide 400 mg + ethambutol 275 mg (HRZE) combination tablets for 8 weeks AND isoniazid 75 mg + rifampicin 150 mg (HR) combination tablets for Weeks 9-26 (total treatment duration 6 months)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rifampicin</intervention_name>
    <description>rifampicin 35 mg/kg</description>
    <arm_group_label>High-dose rifampicin and pyrazinamide</arm_group_label>
    <other_name>rifampin</other_name>
    <other_name>rimactan</other_name>
    <other_name>R</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pyrazinamide</intervention_name>
    <description>pyrazinamide 40 mg/kg</description>
    <arm_group_label>High-dose rifampicin and pyrazinamide</arm_group_label>
    <other_name>Z</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HRZE</intervention_name>
    <description>isoniazid 75 mg + rifampicin 150 mg + pyrazinamide 400 mg + ethambutol 275 mg combination tablets</description>
    <arm_group_label>High-dose rifampicin and pyrazinamide</arm_group_label>
    <other_name>isoniazid</other_name>
    <other_name>H</other_name>
    <other_name>rifampicin</other_name>
    <other_name>R</other_name>
    <other_name>pyrazinamide</other_name>
    <other_name>Z</other_name>
    <other_name>ethambutol</other_name>
    <other_name>E</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HR</intervention_name>
    <description>isoniazid 75 mg + rifampicin 150 mg combination tablets</description>
    <arm_group_label>High-dose rifampicin and pyrazinamide</arm_group_label>
    <other_name>isoniazid</other_name>
    <other_name>H</other_name>
    <other_name>rifampicin</other_name>
    <other_name>R</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient 18 years and older&#xD;
&#xD;
          -  Confirmed pulmonary TB (positive Mtb culture or positive polymerase chain reaction&#xD;
             (PCR) Mtb-complex)&#xD;
&#xD;
          -  Intended to start on first-line TB treatment&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  BMI &gt;17&#xD;
&#xD;
          -  Written Informed Consent&#xD;
&#xD;
          -  Women of childbearing potential should agree on adequate contraceptives during&#xD;
             treatment period and have a negative pregnancy test prior to treatment initiation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not able to provide informed consent/unable to assimilate study information&#xD;
&#xD;
          -  Concomitant infectious disease that requires treatment&#xD;
&#xD;
          -  Known allergy to rifamycins, isoniazid, pyrazinamide, ethambutol or history of severe&#xD;
             sideeffect to any of the drugs&#xD;
&#xD;
          -  Drug-induced inflammatory liver diseases in medical history&#xD;
&#xD;
          -  History of acute liver disease&#xD;
&#xD;
          -  On-going liver disease including hepatitis and elevated transaminase levels &gt;x5 upper&#xD;
             normal limit&#xD;
&#xD;
          -  Porphyria&#xD;
&#xD;
          -  Drug-drug interaction between concomitant drugs and rifampicin that could not be&#xD;
             bridged by dose-adjustment of the concomitant drug&#xD;
&#xD;
          -  Jaundice&#xD;
&#xD;
          -  Acute gout&#xD;
&#xD;
          -  Treatment of active TB during the last year&#xD;
&#xD;
          -  Drug resistance to RIF, INH, PZA or EMB&#xD;
&#xD;
          -  Miliary TB&#xD;
&#xD;
          -  Pulmonary TB with smear positivity grade 3 and/or chest X-ray grading equal to&#xD;
             advanced TB&#xD;
&#xD;
          -  Extrapulmonary TB without pulmonary TB&#xD;
&#xD;
          -  Pregnancy and breast-feeding&#xD;
&#xD;
          -  Immunosuppressive condition&#xD;
&#xD;
          -  Heart failure (NYHA class III and IV)&#xD;
&#xD;
          -  Renal failure with estimated glomerular filtration rate (eGFR) &lt;50 mL/min&#xD;
&#xD;
          -  Dysregulated diabetes mellitus&#xD;
&#xD;
          -  Alcohol and drug abuse&#xD;
&#xD;
          -  Weight &lt;35 kg or &gt;90 kg&#xD;
&#xD;
          -  Participation in other clinical trial (investigating a drug) within the last 30 days&#xD;
             prior to study inclusion&#xD;
&#xD;
          -  Person who the investigator, after consultation with the central contact persons of&#xD;
             the study, finds by other reason than the above listed not suitable for study&#xD;
             participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katarina Niward, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Linkoeping University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katarina Niward, MD, PhD</last_name>
    <phone>+46101030000</phone>
    <email>katarina.niward@liu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jakob Paues, MD, PhD</last_name>
    <phone>+46101030000</phone>
    <email>jakob.paues@liu.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Linköping University Hospital</name>
      <address>
        <city>Linköping</city>
        <zip>S-581 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katarina Niward, MD, PhD</last_name>
      <phone>+46101030000</phone>
      <email>katarina.niward@liu.se</email>
    </contact>
    <contact_backup>
      <last_name>Jakob Paues, MD, PhD</last_name>
      <phone>+46101103000</phone>
      <email>jakob.paues@liu.se</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 23, 2020</study_first_submitted>
  <study_first_submitted_qc>January 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 5, 2021</study_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Linkoeping</investigator_affiliation>
    <investigator_full_name>Katarina Niward</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Drug-susceptible pulmonary tuberculosis</keyword>
  <keyword>Rifampicin</keyword>
  <keyword>Pyrazinamide</keyword>
  <keyword>Shorter tuberculosis treatment</keyword>
  <keyword>Pharmacokinetics/Pharmacodynamics</keyword>
  <keyword>PK/PD</keyword>
  <keyword>TB</keyword>
  <keyword>Adverse event</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Isoniazid</mesh_term>
    <mesh_term>Pyrazinamide</mesh_term>
    <mesh_term>Ethambutol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Needs additional approval (Amendment) from the Ethical Committee in Sweden.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

